Guidelines lacking for patients hospitalized for heart failure

March 26, 2002

CHICAGO --- Over 5 million people in the United States are affected with chronic heart failure (CHF), a condition that results in approximately 1 million hospitalizations annually. Hospitalization usually is associated with a poor prognosis, high hospital readmission rates and death within 30 to 60 days after discharge.

In this patient population, placebo-control, randomized clinical studies, the "gold standard of medicine" from which evidence-based management guidelines normally are derived, are lacking, says heart failure expert Mihai Gheorghiade, M.D., professor of medicine and vice-chief of cardiology at The Feinberg School of Medicine and Northwestern Memorial Hospital.

By contrast, there are many placebo-controlled, randomized clinical studies for other conditions that normally result in hospitalization, namely, acute myocardial infarction (MI), or heart attack.

"When compared to MI, CHF is just as devastating for patients, but there hasn't been nearly the number of large clinical trials," said Duke cardiologist Michael Cuffe, M.D. "The problem is that these trials are very difficult to conduct, and that's what makes this study so important."

Gheorghiade and Cuffe, with co-researchers from Duke University and other medical centers, conducted the first large placebo-controlled, randomized trials of existing therapies for exacerbation of chronic CHF in order to help develop treatment guidelines for this condition.

Results of one of these studies, on the use of milrinone, an intravenous drug administered to increase heart muscle contractility and approved by the FDA to treat worsening CHF, were published in the March 27 issue of the Journal of the American Medical Association.

Results of the other studies, which are investigating the use of beta-blockers, new diuretics or other drugs, are forthcoming from the same group of researchers.

In the current study, 950 patients from 78 medical institutions participated in the so-called OPTIME-CHF, for Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure.

The study evaluated whether the short-term use of milrinone in addition to standard therapy could improve outcomes, i.e., shorten hospitalizations, improved symptoms or improve dosing of life-saving therapies.

The researchers found that the routine addition of IV milrinone, a relatively common intervention for these patients, did not improve outcome, but, rather, was associated with increased early treatment failure, particularly due to new atrial arrhythmias and significant lowering of blood pressure.

The results of the OPTIME-CHF study therefore do not support the routine use of milrinone for patients hospitalized for worsening heart failure, and they point out the importance of evaluating existing therapies or new therapies with placebo-controlled, randomized trial protocols for patients hospitalized with worsening heart failure.

"Milrinone is labeled for use in patients hospitalized with an exacerbation of their CHF. What is significant is that we found over the intermediate term that milrinone not only didn't appear to help these patients, but also was associated with additional problems," Cuffe said.

"The difference between this study and the studies that led to milnirone's approval was that we looked at how the patients actually fared over the longer term, beyond its short-term effects on hemodynamics," he said.
Other researchers on OPTIME-CHF were M. Califf, M.D., and Christopher M. O'Connor, M.D., Duke Clinical Research Institute, Durham, N.C.; Kirkwood F. Adams, Jr., M.D., Heart Failure Program, University of North Carolina at Chapel Hill; Barry M. Massie, M.D., Veterans Administration Medical Center, San Francisco; Ileana Pina, M.D., University Hospital of Cleveland, Cleveland, Ohio; Rebecca Quigg, M.D., Feinberg School of Medicine, Chicago; and Marc A. Silver, M.D., Christ Hospital and Medical Center, Oak Lawn, Ill.

This investigator-initiated study was sponsored by Sanofi-Synthelabo, Inc., New York, N.Y. All authors served as consultants and/or received grants from Sanofi-Synthelabo.

KEYWORDS: chronic heart failure, milrinone, heart disease

Northwestern University

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to